Cargando…

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy

Detalles Bibliográficos
Autores principales:	Patel, Girijesh Kumar, Taylor, William, Singh, Seema, Khushman, Moh’d, Singh, Ajay P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519924/ https://www.ncbi.nlm.nih.gov/pubmed/31105991 http://dx.doi.org/10.4172/2155-9929.1000e129

Ejemplares similares

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping
por: Morelli, Cristina, et al.
Publicado: (2022)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021)

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview
por: Paulsen, Niels Herluf, et al.
Publicado: (2022)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
por: Zhang, Ting, et al.
Publicado: (2023)

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2018)

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
por: Maslarinou, Anthi, et al.
Publicado: (2023)

Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity
por: Hamzic, Seid, et al.
Publicado: (2021)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
por: Ragia, Georgia, et al.
Publicado: (2023)

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene
por: García-González, Xandra, et al.
Publicado: (2018)

P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting
por: Gokare, Prashanth, et al.
Publicado: (2017)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations
por: da Rocha, Jorge E. B., et al.
Publicado: (2021)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
por: Iachetta, Francesco, et al.
Publicado: (2019)

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients
por: Negarandeh, Reza, et al.
Publicado: (2020)

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays
por: De Luca, Ottavia, et al.
Publicado: (2022)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
por: Miarons, Marta, et al.
Publicado: (2023)

The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens
por: Khushman, Moh’d, et al.
Publicado: (2021)

Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer
por: Zeng, Juanzi, et al.
Publicado: (2021)

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach
por: Villalvazo, Priscila, et al.
Publicado: (2021)

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
por: Desilets, Antoine, et al.
Publicado: (2022)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
por: Begré, Ursina B. M., et al.
Publicado: (2022)

DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
por: Wigle, Theodore J., et al.
Publicado: (2019)

The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes
por: Saif, Muhammad W, et al.
Publicado: (2016)

Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with DPYD Genetic Polymorphism: A Systematic Review and Meta-Analysis
por: Kim, Woorim, et al.
Publicado: (2022)

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
por: Saif, Muhammad Wasif, et al.
Publicado: (2020)

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
por: Bukhari, Nedal, et al.
Publicado: (2021)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
por: Hishinuma, Eiji, et al.
Publicado: (2022)

Frequency of the DPYD * 2A allele in the Czech population
por: Koudová, Monika, et al.
Publicado: (2014)

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
por: Lau, David K., et al.
Publicado: (2023)

The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population
por: Abbasian, Mohammad Hadi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_inpjutq92ja05b61mavqbfdpt7